Published on
The FDA approval of Kymriah™ has shifted the paradigm for pediatric cancer treatment — and at Children's Hospital of Philadelphia, more cell therapies are on the horizon.
Published on
Researchers have found key differences among the most common types of pediatric brain tumors that may lead to more effective therapy.
Published on
By identifying common gene variants that raise the risk of an aggressive form of the childhood cancer neuroblastoma, researchers may assist diagnostic efforts.
Published on
This is a game changer for the treatment of pediatric patients battling leukemia and a pivotal milestone in this new era of cellular therapies that treat cancer with a patient’s own immune system.
Published on
Since its inception in October 2016, the workshop has created recommendations for the 50 most common syndromes that predispose children to cancer and produced 16 position papers.
Published on
Newly created videos allow families to see the facilities’ interiors and better understand what will happen during an outpatient visit before their scheduled appointment.
Published on
The experimental, personalized cell therapy that amps up the patient's own immune system has passed a critical milestone in the path to full FDA approval.
Published on
Five years after her T-cell therapy for ALL, Emily remains cancer-free. CHOP has since treated more than 170 patients in clinical trials that have seen a 93% remission rate.
Published on
A DNA-cutting enzyme that regulates gene structure has a broad role in causing certain cancers. This discovery may eventually lead to more precise treatments.
Published on
CHOP researchers reveal how mutations in a protein network drive several high-risk leukemias, offering prospects for new therapies.